Tweetovi

Blokirali ste korisnika/cu @BioLinkAus

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioLinkAus

  1. Prikvačeni tweet
    3. velj

    What a week! Bio-Link was delighted to represent our client, , at . We travelled over 31 km (generally on foot) around San Francisco, meeting with leading pharma executives, sharing the latest exciting data and future strategy for the development of

    Poništi
  2. 12. sij

    Bridging the gap between science & business. Don’t miss out on the Symposium co-hosted by Bio-Link partner and the NSW Stem Cell Network. Come and learn more about accelerating commercialisation of . Register:

    Poništi
  3. 4. stu 2019.

    The Sacred Word: De-risking biotech messaging panel event at was a success! If you’d like to learn more about this subject, read the article () or contact Bio-Link ().

    Poništi
  4. 30. lis 2019.

    Bio-Link's will be representing at ’s annual conference, .

    Poništi
  5. 29. lis 2019.

    Are you interested in global business development for your company? Join us at ’s annual conference, , and meet Bio-Link's Lilly Bojarski, Senior Business Development Associate. Learn more:

    Poništi
  6. 29. lis 2019.

    Bio-Link is pleased to see the progression of a client's technology, as the basis of a $20M Series A funding of Kira Biotech (). The technology was incubated over the last few years through an earlier deal () facilitated by Bio-Link.

    Poništi
  7. 22. lis 2019.

    We are delighted to welcome Kate Samardzic to the Bio-Link team as a Business Development Associate. Learn more about Kate and the rest of the Bio-Link team: .

    Poništi
  8. 21. lis 2019.

    Take a sneak peek at ’s 2019 national conference with Executive Director ’s article “The Sacred Word: De-risking biotech messaging”. Read it in the new edition of Australasian Biotechnology (pg 36):

    Poništi
  9. 8. lis 2019.

    The has launched an initiative in collaboration with and to allow the regulatory review of products to occur in parallel across different countries - Project Orbis. Find out more:

    Poništi
  10. 1. lis 2019.

    Congratulations to for their breakthrough results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial! Results show a significant improvement in cognition in trial participants dosed with Xanamem. ASX Announcement:

    Poništi
  11. 22. ruj 2019.

    Bio-Link is excited to announce our new with !

    Poništi
  12. 3. ruj 2019.

    Over the past year, the industry has witnessed some landmark approvals, high-value merger and acquisition deals and phenomenal venture funding in the US. chart the key trends since June 2018:

    Poništi
  13. 1. ruj 2019.

    If you needed and couldn't afford the $1000/month , would you consider brewing your own drug at home? It is possible! Find out more: (Image source: )

    Poništi
  14. 27. kol 2019.

    The ’s Priority Review Voucher is a great way to expedite the approval of a new drug or biologic, with a decision made in 6 months!

    Poništi
  15. 22. kol 2019.

    We recently reached 100+ followers! Thank you all for your support over the years! We would like to find out what you would like to see more of. Please leave your feedback in the comments below. ; ; ; ; ;

    Poništi
  16. 8. kol 2019.

    is often a challenge in the , but Chipscreen had no such issues, with shares for their IPO being 3000Xs oversubscribed on China’s new tech board! How did this happen? Why did it happen? Most importantly, can we make it happen here in ?

    Poništi
  17. 30. srp 2019.

    Recent analysis of the industry as reported by showed that for most listed large companies, cumulative R&D investment over the past 5 years exceeded sales of new drugs over the same period. Image courtesy

    Poništi
  18. 28. srp 2019.

    Good news for the industry as the “environment is much better than a few years ago”- closed a €400M fund, establishing an "operational platform" for the "drug hunters and the maverick scientists". Source article

    Poništi
  19. 14. srp 2019.

    Boston-based raised $900M for its second . Closer to home, raised $210M for the 5th . We help investors for and provide advisory services to review and develop cases.

    Poništi
  20. 7. srp 2019.

    Several therapeutic candidates testing the amyloid hypothesis in ’s disease (AD) have recently been evaluated in large multicentre Phase III clinical trials, unfortunately without success. Bio-Link's insight into the matter:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·